nitrates has been researched along with Vascular Diseases in 39 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nitric oxide (NO) is a potent vasodilator in the lung, whose bioavailability and signaling pathway are impaired in PAH." | 2.49 | Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics. ( Bueno, M; Gladwin, MT; Mora, AL; Wang, J, 2013) |
| "Nitrates have been commonly used in the therapy of cardiovascular disease for more than 150 years." | 2.47 | [Nitrates in cardiology: current role and areas of uncertainty]. ( Appignani, M; Bellisarii, FI; De Caterina, R; Muscente, F; Radico, F, 2011) |
| "Periodontitis was induced in mice by placement of a ligature for 14 days around the second molar." | 1.91 | Local delivery of nitric oxide prevents endothelial dysfunction in periodontitis. ( Ahluwalia, A; Barnes, MR; Curtis, M; D'Aiuto, F; Fernandes, D; Foster, J; Gee, LC; Goddard, A; Godec, T; Khambata, RS; Massimo, G; Orlandi, M; Ruivo, E; Wade, WG, 2023) |
| " Patients still presented high levels of interleukin (IL)-6, IL-8, and C-reactive protein, and low bioavailability of nitric oxide 7 days after the CABG surgery with CPB." | 1.40 | Post-operative endothelial dysfunction assessment using laser Doppler perfusion measurement in cardiac surgery patients. ( Gomes, MB; Gomes, V; Lessa, MA; Tibirica, E, 2014) |
| " Meanwhile, a most appropriate match of prescription dosage for curing vascular disease was got, which was based on NO value of pharmacodynamics experimental data and the endothelial cells configuration which would changed in a degree when damaged by hydration diamine." | 1.32 | A new experimental design for screening Chinese medicine formula. ( Bo-Chu, W; Chun-Hong, T; Li, Z; Qi, C; Shao-Xi, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.82) | 18.7374 |
| 1990's | 5 (12.82) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 11 (28.21) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Morishima, T | 1 |
| Iemitsu, M | 1 |
| Fujie, S | 1 |
| Ochi, E | 1 |
| Namwong, A | 1 |
| Kumphune, S | 1 |
| Seenak, P | 1 |
| Chotima, R | 1 |
| Nernpermpisooth, N | 1 |
| Malakul, W | 1 |
| Fernandes, D | 1 |
| Khambata, RS | 2 |
| Massimo, G | 2 |
| Ruivo, E | 1 |
| Gee, LC | 1 |
| Foster, J | 1 |
| Goddard, A | 1 |
| Curtis, M | 1 |
| Barnes, MR | 1 |
| Wade, WG | 1 |
| Godec, T | 2 |
| Orlandi, M | 1 |
| D'Aiuto, F | 1 |
| Ahluwalia, A | 2 |
| Münzel, T | 3 |
| Daiber, A | 3 |
| Tawa, M | 1 |
| Nakagawa, K | 1 |
| Ohkita, M | 1 |
| Shabbir, A | 1 |
| Chhetri, I | 1 |
| Parakaw, T | 1 |
| Lau, C | 1 |
| Aubdool, MABN | 1 |
| Dyson, N | 1 |
| Kapil, V | 1 |
| Apea, V | 1 |
| Flint, J | 1 |
| Orkin, C | 1 |
| Rathod, KS | 1 |
| Majumdar, AS | 1 |
| Joshi, PA | 1 |
| Giri, PR | 1 |
| Gomes, V | 1 |
| Gomes, MB | 1 |
| Tibirica, E | 1 |
| Lessa, MA | 1 |
| Steven, S | 1 |
| Weaver, JL | 1 |
| Snyder, R | 1 |
| Knapton, A | 1 |
| Herman, EH | 1 |
| Honchel, R | 1 |
| Miller, T | 1 |
| Espandiari, P | 1 |
| Smith, R | 1 |
| Gu, YZ | 1 |
| Goodsaid, FM | 1 |
| Rosenblum, IY | 1 |
| Sistare, FD | 1 |
| Zhang, J | 1 |
| Hanig, J | 1 |
| Kaur, J | 1 |
| Reddy, K | 1 |
| Balakumar, P | 2 |
| Gori, T | 1 |
| Ude, M | 1 |
| Ude, C | 1 |
| Leuner, K | 1 |
| Bellisarii, FI | 1 |
| Muscente, F | 1 |
| Radico, F | 1 |
| Appignani, M | 1 |
| De Caterina, R | 1 |
| Gentner, NJ | 1 |
| Weber, LP | 1 |
| Alef, MJ | 1 |
| Tzeng, E | 1 |
| Zuckerbraun, BS | 1 |
| Bueno, M | 1 |
| Wang, J | 1 |
| Mora, AL | 1 |
| Gladwin, MT | 1 |
| Kathuria, S | 1 |
| Mahadevan, N | 1 |
| Szabó, C | 1 |
| Mabley, JG | 1 |
| Moeller, SM | 1 |
| Shimanovich, R | 1 |
| Pacher, P | 1 |
| Virag, L | 1 |
| Soriano, FG | 1 |
| Van Duzer, JH | 1 |
| Williams, W | 1 |
| Salzman, AL | 1 |
| Groves, JT | 1 |
| Moore, PK | 1 |
| Marshall, M | 1 |
| ABRAMSON, DI | 1 |
| Migliacci, R | 1 |
| Falcinelli, F | 1 |
| Imperiali, P | 1 |
| Floridi, A | 1 |
| Nenci, GG | 1 |
| Gresele, P | 1 |
| Chun-Hong, T | 1 |
| Bo-Chu, W | 1 |
| Qi, C | 1 |
| Li, Z | 1 |
| Shao-Xi, C | 1 |
| Szocs, K | 1 |
| Meadows, GE | 1 |
| Kotajima, F | 1 |
| Vazir, A | 1 |
| Kostikas, K | 1 |
| Simonds, AK | 1 |
| Morrell, MJ | 1 |
| Corfield, DR | 1 |
| Shah, DI | 1 |
| Singh, M | 1 |
| Lalu, MM | 1 |
| Cena, J | 1 |
| Chowdhury, R | 1 |
| Lam, A | 1 |
| Schulz, R | 1 |
| Gayraud, M | 1 |
| Harris, PJ | 1 |
| Lee, KL | 1 |
| Harrell, FE | 1 |
| Behar, VS | 1 |
| Rosati, RA | 1 |
| Katusic, ZS | 1 |
| Leopold, JA | 1 |
| Loscalzo, J | 1 |
| Carrizo, PH | 1 |
| Dubin, M | 1 |
| Stoppani, AO | 1 |
| Thom, SR | 1 |
| Ohnishi, ST | 1 |
| Fisher, D | 1 |
| Xu, YA | 1 |
| Ischiropoulos, H | 1 |
| Murohara, T | 1 |
| Kugiyama, K | 1 |
| Ota, Y | 1 |
| Doi, H | 1 |
| Ogata, N | 1 |
| Ohgushi, M | 1 |
| Yasue, H | 1 |
| Price, DT | 1 |
| Vita, JA | 1 |
| Keaney, JF | 1 |
| Ruschitzka, F | 1 |
| Quaschning, T | 1 |
| Noll, G | 1 |
| deGottardi, A | 1 |
| Rossier, MF | 1 |
| Enseleit, F | 1 |
| Hürlimann, D | 1 |
| Lüscher, TF | 1 |
| Shaw, SG | 1 |
| Strano, A | 1 |
| Novo, S | 1 |
| Shub, C | 1 |
| Vlietstra, RE | 1 |
| McGoon, MD | 1 |
| Novák, J | 1 |
| Gavallér, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension[NCT01431313] | Phase 2 | 48 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Effects of Oral Antioxidant Cocktail on Vascular Function and Blood Flow in Cardiovascular Disease Patients[NCT03629613] | 0 participants (Actual) | Interventional | 2020-12-01 | Withdrawn (stopped due to discontinued due to change in operating plans prior to study initiation and enrollment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basal platelet oxygen consumption measured in isolated platelets by extracellular flux analysis (XF24, Seahorse Biosciences, Billerica, MA). (NCT01431313)
Timeframe: Maximal effect at 15 minutes post 45mg or 90mg inhalation vs Pre dose
| Intervention | picomoles O2/min (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -17.58 |
| WHO Group II Pulmonary Hypertension (PH) | 8.62 |
| WHO Group III Pulmonary Hypertension (PH) | -11.64 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of plasma nitrite concentrations in mixed venous blood over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.9 |
| WHO Group II Pulmonary Hypertension (PH) | 7.0 |
| WHO Group III Pulmonary Hypertension (PH) | 7.4 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of pulmonary artery occlusion (capillary) pullback nitrite concentration over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.2 |
| WHO Group III Pulmonary Hypertension (PH) | 2.4 |
Characteristic impedance (Zc) which may be related to compliance effects in the large, conduit arteries. (NCT01431313)
Timeframe: Pre dose and 60 minutes post last dosage inhaled
| Intervention | dyne*sec/cm5 (Median) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.004 |
| WHO Group II Pulmonary Hypertension (PH) | -0.34 |
| WHO Group III Pulmonary Hypertension (PH) | -0.20 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since pulmonary vascular resistance (PVR) was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of PVR over all subsequent times and doses (beta from the mixed effects model, converted back from natural log to Woods units), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | Woods units (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 0.77 |
| WHO Group II Pulmonary Hypertension (PH) | 0.40 |
| WHO Group III Pulmonary Hypertension (PH) | -0.39 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of MAP over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -5.1 |
| WHO Group II Pulmonary Hypertension (PH) | -3.4 |
| WHO Group III Pulmonary Hypertension (PH) | -9.5 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since systemic vascular resistance was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of SVR over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg⋅min/L (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.43 |
| WHO Group II Pulmonary Hypertension (PH) | 1.19 |
| WHO Group III Pulmonary Hypertension (PH) | -2.04 |
Time in minutes to maximum PVR decrease. During study procedure, hemodynamics were measured at 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose. The time point at which each patient's maximal decrease in PVR occurred was recorded and reported as the mean and standard deviation in each cohort. (NCT01431313)
Timeframe: 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose
| Intervention | minutes (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 42.0 |
| WHO Group II Pulmonary Hypertension (PH) | 33.0 |
| WHO Group III Pulmonary Hypertension (PH) | 42.5 |
15 reviews available for nitrates and Vascular Diseases
| Article | Year |
|---|---|
Vascular Redox Signaling, Endothelial Nitric Oxide Synthase Uncoupling, and Endothelial Dysfunction in the Setting of Transportation Noise Exposure or Chronic Treatment with Organic Nitrates.
Topics: Cardiovascular Diseases; Endothelium, Vascular; Humans; Nitrates; Nitric Oxide; Nitric Oxide Synthas | 2023 |
Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction.
Topics: Animals; Drug Tolerance; Endothelium, Vascular; Humans; Nitrates; Vascular Diseases; Vasodilation; V | 2014 |
[Mechanisms and clinical significance of nitrate tolerance].
Topics: Aldehyde Dehydrogenase; Angina Pectoris; Animals; Drug Tolerance; Heart Failure; Humans; Nitrates; O | 2010 |
[Nitrates and PDE5 inhibitors: pharmaceutical care].
Topics: Erectile Dysfunction; Humans; Male; Nitrates; Pharmaceutical Services; Pharmacies; Phosphodiesterase | 2010 |
[Nitrates in cardiology: current role and areas of uncertainty].
Topics: Cardiovascular Diseases; Drug Tolerance; Heart Failure; Humans; Myocardial Ischemia; Nitrates; Pract | 2011 |
Nitric oxide and nitrite-based therapeutic opportunities in intimal hyperplasia.
Topics: Animals; Humans; Hyperplasia; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Tunica Intima; | 2012 |
Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics.
Topics: Animals; Humans; Hypertension, Pulmonary; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Vas | 2013 |
Nitric oxide releasing acetaminophen (nitroacetaminophen).
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease M | 2003 |
Endothelial dysfunction and reactive oxygen species production in ischemia/reperfusion and nitrate tolerance.
Topics: Animals; Antioxidants; Blood Vessels; Drug Tolerance; Endothelium, Vascular; Humans; Nitrates; Nitri | 2004 |
Raynaud's phenomenon.
Topics: Adrenergic alpha-Antagonists; Angiotensin Receptor Antagonists; Connective Tissue Diseases; Endocrin | 2007 |
Superoxide anion and endothelial regulation of arterial tone.
Topics: Animals; Arteries; Endothelium, Vascular; Homeostasis; Humans; Models, Cardiovascular; Muscle Tonus; | 1996 |
New developments in nitrosovasodilator therapy.
Topics: Humans; Nitrates; Nitric Oxide; Vascular Diseases; Vasodilator Agents | 1997 |
Redox control of vascular nitric oxide bioavailability.
Topics: Animals; Antioxidants; Biological Availability; Blood Vessels; Catalase; Glutathione Peroxidase; Hum | 2000 |
[Calcium antagonists in cardiology].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium; Coronary Disease; Human | 1978 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel | 1985 |
2 trials available for nitrates and Vascular Diseases
| Article | Year |
|---|---|
Prior beetroot juice ingestion offsets endothelial dysfunction following prolonged sitting.
Topics: Beta vulgaris; Blood Pressure; Dietary Supplements; Double-Blind Method; Eating; Female; Fruit and V | 2022 |
A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study.
Topics: COVID-19; COVID-19 Vaccines; Female; Humans; Male; Nitrates; Pulse Wave Analysis; Randomized Control | 2023 |
22 other studies available for nitrates and Vascular Diseases
| Article | Year |
|---|---|
Pineapple fruit improves vascular endothelial dysfunction, hepatic steatosis, and cholesterol metabolism in rats fed a high-cholesterol diet.
Topics: Ananas; Animals; Antioxidants; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Diet; Fatty Liver; Frui | 2022 |
Local delivery of nitric oxide prevents endothelial dysfunction in periodontitis.
Topics: Animals; Endothelium, Vascular; Mice; Nitrates; Nitric Oxide; Nitrites; Periodontitis; Vascular Dise | 2023 |
Effects of beetroot juice supplementation on vascular functional and structural changes in aged mice.
Topics: Acetylcholine; Animals; Antioxidants; Dietary Supplements; Mice; Nitrates; Vascular Diseases | 2023 |
Resveratrol attenuated smokeless tobacco-induced vascular and metabolic complications in ovariectomized rats.
Topics: Animals; Aorta; Collagen; Diabetes Complications; Diabetes Mellitus; Estradiol; Female; Glucose Tole | 2013 |
Post-operative endothelial dysfunction assessment using laser Doppler perfusion measurement in cardiac surgery patients.
Topics: Acetylcholine; Capillaries; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Byp | 2014 |
Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385.
Topics: Animals; Biomarkers; Blood Vessels; Clinical Chemistry Tests; Cyclic N-Oxides; Dose-Response Relatio | 2008 |
The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat.
Topics: Animals; Arsenites; Cholesterol; Endothelium, Vascular; Fenofibrate; Hypolipidemic Agents; In Vitro | 2010 |
Secondhand tobacco smoke, arterial stiffness, and altered circadian blood pressure patterns are associated with lung inflammation and oxidative stress in rats.
Topics: Animals; Blood Pressure; Circadian Rhythm; Endothelium, Vascular; Male; Nitrates; Nitric Oxide; Nitr | 2012 |
Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.
Topics: Anilides; Animals; Endothelium, Vascular; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductas | 2013 |
Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst.
Topics: Animals; Catalysis; Cytoprotection; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Re | 2002 |
DRUGS USED IN PERIPHERAL VASCULAR DISEASES.
Topics: Deoxyribonuclease I; Dihydroergotoxine; Endopeptidases; Ergot Alkaloids; Ganglionic Blockers; Histam | 1963 |
Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Cyclic GMP; Diastole; Endothelium, Vascular; Female; Homocy | 2004 |
A new experimental design for screening Chinese medicine formula.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Chinese Herb | 2004 |
Overnight changes in the cerebral vascular response to isocapnic hypoxia and hypercapnia in healthy humans: protection against stroke.
Topics: Adult; Brain; Cerebrovascular Circulation; Humans; Hypercapnia; Hypoxia; Ischemia; Male; Middle Cere | 2005 |
Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
Topics: Animals; Blood Pressure; Endothelins; Lipid Metabolism; Male; Microscopy, Electron, Scanning; Nitrat | 2006 |
Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction.
Topics: Animals; Aorta, Thoracic; Blotting, Western; Collagenases; Endotoxemia; Endotoxins; Gelatinases; In | 2006 |
Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death.
Topics: Adrenergic beta-Antagonists; Cardiac Catheterization; Cardiovascular Diseases; Coronary Disease; Hea | 1980 |
[Physiopathologic effects of nitric oxide and their relationship with oxidative stress].
Topics: Antioxidants; Humans; Liver Transplantation; Neoplasms; Neurodegenerative Diseases; Nitrates; Nitric | 1998 |
Pulmonary vascular stress from carbon monoxide.
Topics: Animals; Capillaries; Carbon Monoxide; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Hydr | 1999 |
Effects of atrial and brain natriuretic peptides on lysophosphatidylcholine-mediated endothelial dysfunction.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Atrial Natriuretic Factor; Cattle; Coronary Vessels | 1999 |
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, C | 2001 |
[The effect of bencyclane on burns and other functional vascular disorders].
Topics: Blood Circulation; Burns; Cycloheptanes; Ethanolamines; Fumarates; Humans; Leg; Nitrates; Oscillomet | 1970 |